FDA approves drug to treat 2 types of AMLAugust 4, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
FDA approves enasidenib to treat relapsed/refractory AMLAugust 2, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
FDA grants acalabrutinib breakthrough designationAugust 2, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
ASCO updates guidelines on antiemetic use in cancer patientsAugust 1, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaHematology NursingPediatricsPharmacyRelated Issues
FDA grants drug breakthrough designation for AMLJuly 30, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
Product granted fast track designation for aTTPJuly 27, 2017AnemiaThrombosisPharmacyBleeding Disorders
Health Canada approves new use for brentuximab vedotinJuly 26, 2017Lymphoma & Plasma Cell DisordersPharmacyHodgkin LymphomaAggressive Lymphomas
FDA grants orphan designation to gilteritinib in AMLJuly 21, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
Blinatumomab granted full approval to treat rel/ref BCP-ALLJuly 13, 2017Leukemia, Myelodysplasia, TransplantationPharmacyALL
Benefits of gemtuzumab ozogamicin outweigh risks, ODAC saysJuly 13, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
